{"protocolSection": {"identificationModule": {"nctId": "NCT01716754", "orgStudyIdInfo": {"id": "CQGE031B2201"}, "secondaryIdInfos": [{"id": "2012-002298-69", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma", "officialTitle": "A Multi-center, Randomized, Double-blind, Placebo and Active-controlled Study With Exploratory Dose-ranging to Investigate the Efficacy and Safety of 16 Weeks Treatment With Subcutaneous (s.c.) QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting \u03b22-agonists"}, "statusModule": {"statusVerifiedDate": "2017-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-12"}, "primaryCompletionDateStruct": {"date": "2016-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2016-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2012-10-19", "studyFirstSubmitQcDate": "2012-10-25", "studyFirstPostDateStruct": {"date": "2012-10-30", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2017-01-18", "resultsFirstSubmitQcDate": "2017-01-18", "resultsFirstPostDateStruct": {"date": "2017-03-08", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2017-08-07", "lastUpdatePostDateStruct": {"date": "2017-08-11", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study assessed the effect on asthma control of different dose levels and regimens of QGE031 in asthma patients that are inadequately controlled with inhaled steroid and beta-2 agonist medication. Safety was assessed also. Comparison was to placebo and omalizumab. Information from this study was planned to support the design of future studies."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["asthma", "asthma control", "allergy", "atopic", "IgE", "double-blind", "placebo", "omalizumab"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 471, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "QGE031 240 mg every 2 weeks (q2w)", "type": "EXPERIMENTAL", "description": "Participants received QGE031 240 mg subcutaneously (s.c.) q2w for 16 weeks.", "interventionNames": ["Drug: QGE031"]}, {"label": "QGE031 240 mg q4w", "type": "EXPERIMENTAL", "description": "Participants received QGE031 240 mg s.c. q4w for 16 weeks.", "interventionNames": ["Drug: QGE031"]}, {"label": "QGE031 180 mg q2w", "type": "EXPERIMENTAL", "description": "Participants received QGE031 180 mg s.c. q2w for 16 weeks.", "interventionNames": ["Drug: QGE031"]}, {"label": "QGE031 120 mg q2w", "type": "EXPERIMENTAL", "description": "Participants received QGE031 120 mg s.c. q2w for 16 weeks.", "interventionNames": ["Drug: QGE031"]}, {"label": "QGE031 36 mg q2w", "type": "EXPERIMENTAL", "description": "Participants received QGE031 36 mg s.c. q2w for 16 weeks.", "interventionNames": ["Drug: QGE031"]}, {"label": "QGE031 12 mg q2w", "type": "EXPERIMENTAL", "description": "Participants received QGE031 12 mg s.c. q2w for 16 weeks.", "interventionNames": ["Drug: QGE031"]}, {"label": "Omalizumab (as per locally approved dosing table)", "type": "ACTIVE_COMPARATOR", "description": "Participants received omalizumab as per locally approved dosing table s.c. q2w or q4w for 16 weeks.", "interventionNames": ["Drug: Omalizumab"]}, {"label": "Placebo to QGE031 240 mg q2w", "type": "PLACEBO_COMPARATOR", "description": "Participants received matching placebo to QGE031 240 mg s.c. q2w for 16 weeks.", "interventionNames": ["Drug: Placebo"]}, {"label": "Placebo to QGE031 240 mg q4w", "type": "PLACEBO_COMPARATOR", "description": "Participants received placebo to QGE031 240 mg s.c. q2w for 16 weeks.", "interventionNames": ["Drug: Placebo"]}, {"label": "Placebo to QGE031 180 mg q2w", "type": "PLACEBO_COMPARATOR", "description": "Participants received QGE031 180 mg s.c. q2w for 16 weeks.", "interventionNames": ["Drug: Placebo"]}, {"label": "Placebo to QGE031 120 mg q2w", "type": "PLACEBO_COMPARATOR", "description": "Participants received QGE031 120 mg s.c. q2w for 16 weeks.", "interventionNames": ["Drug: Placebo"]}, {"label": "Placebo to QGE031 36 mg q2w", "type": "PLACEBO_COMPARATOR", "description": "Participants received QGE031 36 mg s.c. q2w for 16 weeks.", "interventionNames": ["Drug: Placebo"]}, {"label": "Placebo to QGE031 12 mg q2w", "type": "PLACEBO_COMPARATOR", "description": "Participants received QGE031 12 mg s.c. q2w for 16 weeks.", "interventionNames": ["Drug: Placebo"]}, {"label": "Placebo to omalizumab", "type": "PLACEBO_COMPARATOR", "description": "Participants received placebo to omalizumab s.c. q2w or q4w for 16 weeks.", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "QGE031", "description": "QGE031 was supplied as 120 mg liquid in vial per 1 mL", "armGroupLabels": ["QGE031 12 mg q2w", "QGE031 120 mg q2w", "QGE031 180 mg q2w", "QGE031 240 mg every 2 weeks (q2w)", "QGE031 240 mg q4w", "QGE031 36 mg q2w"]}, {"type": "DRUG", "name": "Omalizumab", "description": "Omalizumab was supplied as 150 mg lyophilisate in vial", "armGroupLabels": ["Omalizumab (as per locally approved dosing table)"], "otherNames": ["Xolair"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo to QGE031 and Omalizumab was supplied as QGE031 0 mg in vial per 1 mL", "armGroupLabels": ["Placebo to QGE031 12 mg q2w", "Placebo to QGE031 120 mg q2w", "Placebo to QGE031 180 mg q2w", "Placebo to QGE031 240 mg q2w", "Placebo to QGE031 240 mg q4w", "Placebo to QGE031 36 mg q2w", "Placebo to omalizumab"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Percentage of QGE031 Participants With Clinically Important Improvement of <= -0.5 in the Asthma Control Questionnaire 7 (ACQ-7) Score Compared to Placebo", "description": "The ACQ-7 measures asthma symptom control and consisted of 7 items: 5 on symptom assessment, 1 on rescue bronchodilator use and 1 on airway caliber (FEV1 % predicted). All 7 questions of the ACQ were equally weighted. Items 1-6 scored along a 7-point response scale, where 0 = good controlled and 6 = poor controlled. The 7th item on % predicted FEV1 (pre-bronchodilator) was scored by clinic staff on a 7-point scale (0 - \\> 95%; 1 - 90-95%; 2 - 80-89%; 3 - 70-79%; 4 - 60-69%; 5 - 50-59%; 6 - \\< 50%). The average score of the 7 questions was calculated as the sum of scores divided by the number of questions that were answered by the participants, as long as there were at least 6 questions answered and the missing items were neither question 1 nor question 7.", "timeFrame": "Week 16"}], "secondaryOutcomes": [{"measure": "Change From Baseline in ACQ-7 Score", "description": "The ACQ-7 measures asthma symptom control and consisted of 7 items: 5 on symptom assessment, 1 on rescue bronchodilator use and 1 on airway caliber (FEV1 % predicted). All 7 questions of the ACQ were equally weighted. Items 1-6 scored along a 7-point response scale, where 0 = good controlled and 6 = poor controlled. The 7th item on % predicted FEV1 (pre-bronchodilator) was scored by clinic staff on a 7-point scale (0 - \\> 95%; 1 - 90-95%; 2 - 80-89%; 3 - 70-79%; 4 - 60-69%; 5 - 50-59%; 6 - \\< 50%). The average score of the 7 questions was calculated as the sum of scores divided by the number of questions that were answered by the participants, as long as there were at least 6 questions answered and the missing items were neither question 1 nor question 7. A negative change from baseline indicates improvement.", "timeFrame": "Baseline, Weeks 4, 8, 12, 16 and 28"}, {"measure": "Percentage of Participants With a Change From Baseline in ACQ-7 Score Less Than -1.1", "description": "The ACQ-7 measures asthma symptom control and consisted of 7 items: 5 on symptom assessment, 1 on rescue bronchodilator use and 1 on airway caliber (FEV1 % predicted). All 7 questions of the ACQ were equally weighted. Items 1-6 scored along a 7-point response scale, where 0 = good controlled and 6 = poor controlled. The 7th item on % predicted FEV1 (pre-bronchodilator) was scored by clinic staff on a 7-point scale (0 - \\> 95%; 1 - 90-95%; 2 - 80-89%; 3 - 70-79%; 4 - 60-69%; 5 - 50-59%; 6 - \\< 50%). The average score of the 7 questions was calculated as the sum of scores divided by the number of questions that were answered by the participants, as long as there were at least 6 questions answered and the missing items were neither question 1 nor question 7.", "timeFrame": "Week 16"}, {"measure": "Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Score", "description": "The AQLQ is a 32-item disease specific questionnaire designed to measure functional impairments that are most important to participants with asthma. The 32 items in the AQLQ were divided into four domain-specific scores and a total score as follows: Activity limitations = Mean of Items 1, 2, 3, 4, 5, 11, 19, 25, 28, 31, 32 (11 items); Symptoms = Mean of Items 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 29, 30 (12 items); Emotional function = Mean of Items 7, 13, 15, 21, 27 (5 items); Environmental stimuli = Mean of Items 9, 17, 23, 26 (4 items); and Overall Score = Mean of Items 1 to 32 (32 items). Each item of the AQLQ was equally weighted and scored along a 7-point scale, where 1 indicates maximal impairment and 7 indicates no impairment. Thus, higher scores indicate better asthma-related quality of life. The mean overall score ranged from 1 to 7. A positive change from baseline indicates improvement.", "timeFrame": "Baseline, Week 16, Week 28"}, {"measure": "Change From Baseline in Mean Number of Puffs of Morning, Evening and Total Daily Asthma Rescue Medication", "description": "Participants recorded their use of rescue medication into an electronic diary (eDiary). A negative change from baseline indicates improvement.", "timeFrame": "Baseline, Week 16"}]}, "eligibilityModule": {"eligibilityCriteria": "Key Inclusion Criteria:\n\n* A diagnosis of allergic asthma , uncontrolled on current medication.\n* History of at least 1 asthma exacerbation during the last 1 year\n* Forced Expiratory Volume in one second (FEV1) of \u2265 40% and \u2264 80% of the predicted normal value; reversibility following administration of bronchodilator must also be demonstrated (historical positive reversibility or bronchoprovocation result can be used).\n\nKey Exclusion Criteria:\n\n* Baseline IgE levels or body weight outside the omalizumab dosing table.\n* Use of tobacco products within the previous 6 months (Social occasional smokers may be included).\n* Recent asthma attack/exacerbation or asthma worsening/ respiratory infection.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Novartis Investigative Site", "city": "Fresno", "state": "California", "zip": "93720", "country": "United States", "geoPoint": {"lat": 36.74773, "lon": -119.77237}}, {"facility": "Novartis Investigative Site", "city": "Hawaiian Gardens", "state": "California", "zip": "90716", "country": "United States", "geoPoint": {"lat": 33.8314, "lon": -118.07284}}, {"facility": "Novartis Investigative Site", "city": "Riverside", "state": "California", "zip": "92506", "country": "United States", "geoPoint": {"lat": 33.95335, "lon": -117.39616}}, {"facility": "Novartis Investigative Site", "city": "San Jose", "state": "California", "zip": "95117", "country": "United States", "geoPoint": {"lat": 37.33939, "lon": -121.89496}}, {"facility": "Novartis Investigative Site", "city": "Vista", "state": "California", "zip": "92083", "country": "United States", "geoPoint": {"lat": 33.20004, "lon": -117.24254}}, {"facility": "Novartis Investigative Site", "city": "Evansville", "state": "Indiana", "zip": "47713", "country": "United States", "geoPoint": {"lat": 37.97476, "lon": -87.55585}}, {"facility": "Novartis Investigative Site", "city": "Owensboro", "state": "Kentucky", "zip": "42301", "country": "United States", "geoPoint": {"lat": 37.77422, "lon": -87.11333}}, {"facility": "Novartis Investigative Site", "city": "Columbia", "state": "Maryland", "zip": "21044", "country": "United States", "geoPoint": {"lat": 39.24038, "lon": -76.83942}}, {"facility": "Novartis Investigative Site", "city": "Waldorf", "state": "Maryland", "zip": "20602", "country": "United States", "geoPoint": {"lat": 38.62456, "lon": -76.93914}}, {"facility": "Novartis Investigative Site", "city": "Novi", "state": "Michigan", "zip": "48375", "country": "United States", "geoPoint": {"lat": 42.48059, "lon": -83.47549}}, {"facility": "Novartis Investigative Site", "city": "Minneapolis", "state": "Minnesota", "zip": "55402", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": "Novartis Investigative Site", "city": "Omaha", "state": "Nebraska", "zip": "68130", "country": "United States", "geoPoint": {"lat": 41.25626, "lon": -95.94043}}, {"facility": "Novartis Investigative Site", "city": "Papillion", "state": "Nebraska", "zip": "68046", "country": "United States", "geoPoint": {"lat": 41.15444, "lon": -96.04224}}, {"facility": "Novartis Investigative Site", "city": "Brooklyn", "state": "New York", "zip": "11229", "country": "United States", "geoPoint": {"lat": 40.6501, "lon": -73.94958}}, {"facility": "Novartis Investigative Site", "city": "Mineola", "state": "New York", "zip": "11501", "country": "United States", "geoPoint": {"lat": 40.74927, "lon": -73.64068}}, {"facility": "Novartis Investigative Site", "city": "Cincinnati", "state": "Ohio", "zip": "45231", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Novartis Investigative Site", "city": "Lincoln", "state": "Rhode Island", "zip": "02865", "country": "United States", "geoPoint": {"lat": 41.92111, "lon": -71.435}}, {"facility": "Novartis Investigative Site", "city": "Mount Pleasant", "state": "South Carolina", "zip": "29464", "country": "United States", "geoPoint": {"lat": 32.79407, "lon": -79.86259}}, {"facility": "Novartis Investigative Site", "city": "Summerville", "state": "South Carolina", "zip": "29485", "country": "United States", "geoPoint": {"lat": 33.0185, "lon": -80.17565}}, {"facility": "Novartis Investigative Site", "city": "Salt Lake City", "state": "Utah", "zip": "84108", "country": "United States", "geoPoint": {"lat": 40.76078, "lon": -111.89105}}, {"facility": "Novartis Investigative Site", "city": "Fairfax", "state": "Virginia", "zip": "22030", "country": "United States", "geoPoint": {"lat": 38.84622, "lon": -77.30637}}, {"facility": "Novartis Investigative Site", "city": "Everett", "state": "Washington", "zip": "98208", "country": "United States", "geoPoint": {"lat": 47.97898, "lon": -122.20208}}, {"facility": "Novartis Investigative Site", "city": "Caba", "state": "Buenos Aires", "zip": "C1122AAK", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Novartis Investigative Site", "city": "Caba", "state": "Buenos Aires", "zip": "C1426ABP", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Novartis Investigative Site", "city": "Mar del Plata", "state": "Buenos Aires", "zip": "7600", "country": "Argentina", "geoPoint": {"lat": -38.00228, "lon": -57.55754}}, {"facility": "Novartis Investigative Site", "city": "Caba", "state": "Capital Federal", "zip": "C1430CKE", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Novartis Investigative Site", "city": "Santa Fe", "state": "Rosario", "zip": "S2000DBS", "country": "Argentina", "geoPoint": {"lat": -31.63333, "lon": -60.7}}, {"facility": "Novartis Investigative Site", "city": "Rosario", "state": "Santa Fe", "zip": "S2000AII", "country": "Argentina", "geoPoint": {"lat": -32.94682, "lon": -60.63932}}, {"facility": "Novartis Investigative Site", "city": "Rosario", "state": "Santa Fe", "zip": "S2000CXH", "country": "Argentina", "geoPoint": {"lat": -32.94682, "lon": -60.63932}}, {"facility": "Novartis Investigative Site", "city": "San Miguel de Tucuman", "state": "Tucuman", "zip": "4000", "country": "Argentina", "geoPoint": {"lat": -26.82414, "lon": -65.2226}}, {"facility": "Novartis Investigative Site", "city": "Buenos Aires", "zip": "B1842DID", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Novartis Investigative Site", "city": "Buenos Aires", "zip": "C1125ABE", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Novartis Investigative Site", "city": "Mendoza", "zip": "M5500CBA", "country": "Argentina", "geoPoint": {"lat": -32.89084, "lon": -68.82717}}, {"facility": "Novartis Investigative Site", "city": "Mendoza", "zip": "M5500FIK", "country": "Argentina", "geoPoint": {"lat": -32.89084, "lon": -68.82717}}, {"facility": "Novartis Investigative Site", "city": "Santa Fe", "zip": "S3000FIL", "country": "Argentina", "geoPoint": {"lat": -31.63333, "lon": -60.7}}, {"facility": "Novartis Investigative Site", "city": "Ottawa", "state": "Ontario", "zip": "K1Y 4G2", "country": "Canada", "geoPoint": {"lat": 45.41117, "lon": -75.69812}}, {"facility": "Novartis Investigative Site", "city": "Montreal", "state": "Quebec", "zip": "H3G 1L5", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "Novartis Investigative Site", "city": "St-Charles-Borrom\u00e9e", "state": "Quebec", "zip": "J6E 2B4", "country": "Canada", "geoPoint": {"lat": 46.05007, "lon": -73.46586}}, {"facility": "Novartis Investigative Site", "city": "Quebec", "zip": "G1V 4W2", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}, {"facility": "Novartis Investigative Site", "city": "Brno", "state": "Czech Republic", "zip": "639 00", "country": "Czechia", "geoPoint": {"lat": 49.19522, "lon": 16.60796}}, {"facility": "Novartis Investigative Site", "city": "Trutnov", "state": "Czech Republic", "zip": "541 01", "country": "Czechia", "geoPoint": {"lat": 50.56101, "lon": 15.9127}}, {"facility": "Novartis Investigative Site", "city": "Teplice", "state": "CZE", "zip": "415 01", "country": "Czechia", "geoPoint": {"lat": 50.6404, "lon": 13.82451}}, {"facility": "Novartis Investigative Site", "city": "Breclav", "zip": "690 02", "country": "Czechia", "geoPoint": {"lat": 48.75897, "lon": 16.88203}}, {"facility": "Novartis Investigative Site", "city": "Brno", "zip": "615 00", "country": "Czechia", "geoPoint": {"lat": 49.19522, "lon": 16.60796}}, {"facility": "Novartis Investigative Site", "city": "Tabor", "zip": "390 01", "country": "Czechia", "geoPoint": {"lat": 49.41441, "lon": 14.6578}}, {"facility": "Novartis Investigative Site", "city": "Helsinki", "zip": "00290", "country": "Finland", "geoPoint": {"lat": 60.16952, "lon": 24.93545}}, {"facility": "Novartis Investigative Site", "city": "Tampere", "zip": "33520", "country": "Finland", "geoPoint": {"lat": 61.49911, "lon": 23.78712}}, {"facility": "Novartis Investigative Site", "city": "Turku", "zip": "20521", "country": "Finland", "geoPoint": {"lat": 60.45148, "lon": 22.26869}}, {"facility": "Novartis Investigative Site", "city": "Le Kremlin Bicetre", "zip": "94275", "country": "France", "geoPoint": {"lat": 48.81471, "lon": 2.36073}}, {"facility": "Novartis Investigative Site", "city": "Marseille", "zip": "13915", "country": "France", "geoPoint": {"lat": 43.29551, "lon": 5.38958}}, {"facility": "Novartis Investigative Site", "city": "Montpellier", "zip": "34059", "country": "France", "geoPoint": {"lat": 43.61092, "lon": 3.87723}}, {"facility": "Novartis Investigative Site", "city": "Strasbourg", "zip": "67091", "country": "France", "geoPoint": {"lat": 48.58392, "lon": 7.74553}}, {"facility": "Novartis Investigative Site", "city": "Frankfurt", "zip": "60596", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "Novartis Investigative Site", "city": "Hamburg", "zip": "20354", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"facility": "Novartis Investigative Site", "city": "Homburg", "zip": "66421", "country": "Germany", "geoPoint": {"lat": 49.32637, "lon": 7.33867}}, {"facility": "Novartis Investigative Site", "city": "Leipzig", "zip": "04103", "country": "Germany", "geoPoint": {"lat": 51.33962, "lon": 12.37129}}, {"facility": "Novartis Investigative Site", "city": "Leipzig", "zip": "04275", "country": "Germany", "geoPoint": {"lat": 51.33962, "lon": 12.37129}}, {"facility": "Novartis Investigative Site", "city": "Mainz", "zip": "55131", "country": "Germany", "geoPoint": {"lat": 49.98419, "lon": 8.2791}}, {"facility": "Novartis Investigative Site", "city": "Roth", "zip": "91154", "country": "Germany", "geoPoint": {"lat": 49.24762, "lon": 11.09111}}, {"facility": "Novartis Investigative Site", "city": "R\u00fcdersdorf", "zip": "15562", "country": "Germany", "geoPoint": {"lat": 51.1, "lon": 11.45}}, {"facility": "Novartis Investigative Site", "city": "Guatemala City", "state": "GTM", "zip": "01010", "country": "Guatemala", "geoPoint": {"lat": 14.64072, "lon": -90.51327}}, {"facility": "Novartis Investigative Site", "city": "Guatemala City", "state": "GTM", "zip": "01011", "country": "Guatemala", "geoPoint": {"lat": 14.64072, "lon": -90.51327}}, {"facility": "Novartis Investigative Site", "city": "Guatemala City", "zip": "01011", "country": "Guatemala", "geoPoint": {"lat": 14.64072, "lon": -90.51327}}, {"facility": "Novartis Investigative Site", "city": "Budapest", "zip": "1121", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Novartis Investigative Site", "city": "Debrecen", "zip": "4032", "country": "Hungary", "geoPoint": {"lat": 47.53333, "lon": 21.63333}}, {"facility": "Novartis Investigative Site", "city": "Pecs", "zip": "7635", "country": "Hungary", "geoPoint": {"lat": 46.08333, "lon": 18.23333}}, {"facility": "Novartis Investigative Site", "city": "Torokbalint", "zip": "2045", "country": "Hungary", "geoPoint": {"lat": 47.42931, "lon": 18.91356}}, {"facility": "Novartis Investigative Site", "city": "Panjim", "state": "Goa", "zip": "403 002", "country": "India", "geoPoint": {"lat": 15.49574, "lon": 73.82624}}, {"facility": "Novartis Investigative Site", "city": "Karamsad", "state": "Gujrat", "zip": "388325", "country": "India", "geoPoint": {"lat": 22.54243, "lon": 72.90392}}, {"facility": "Novartis Investigative Site", "city": "Dhantoli", "state": "Nagpur", "zip": "12", "country": "India", "geoPoint": {"lat": 27.83004, "lon": 77.86467}}, {"facility": "Novartis Investigative Site", "city": "Haifa", "zip": "3436212", "country": "Israel", "geoPoint": {"lat": 32.81841, "lon": 34.9885}}, {"facility": "Novartis Investigative Site", "city": "Jerusalem", "zip": "91031", "country": "Israel", "geoPoint": {"lat": 31.76904, "lon": 35.21633}}, {"facility": "Novartis Investigative Site", "city": "Jerusalem", "zip": "9112001", "country": "Israel", "geoPoint": {"lat": 31.76904, "lon": 35.21633}}, {"facility": "Novartis Investigative Site", "city": "Kfar-Saba", "zip": "4428164", "country": "Israel", "geoPoint": {"lat": 32.175, "lon": 34.90694}}, {"facility": "Novartis Investigative Site", "city": "Petach Tikva", "zip": "49100", "country": "Israel", "geoPoint": {"lat": 32.08707, "lon": 34.88747}}, {"facility": "Novartis Investigative Site", "city": "Rehovot", "zip": "7610001", "country": "Israel", "geoPoint": {"lat": 31.89421, "lon": 34.81199}}, {"facility": "Novartis Investigative Site", "city": "Messina", "state": "ME", "zip": "98125", "country": "Italy", "geoPoint": {"lat": 38.19394, "lon": 15.55256}}, {"facility": "Novartis Investigative Site", "city": "Milano", "state": "MI", "zip": "20123", "country": "Italy", "geoPoint": {"lat": 45.46427, "lon": 9.18951}}, {"facility": "Novartis Investigative Site", "city": "Padova", "state": "PD", "zip": "35128", "country": "Italy", "geoPoint": {"lat": 45.40797, "lon": 11.88586}}, {"facility": "Novartis Investigative Site", "city": "Pisa", "state": "PI", "zip": "56124", "country": "Italy", "geoPoint": {"lat": 43.70853, "lon": 10.4036}}, {"facility": "Novartis Investigative Site", "city": "Reggio Emilia", "state": "RE", "zip": "42123", "country": "Italy", "geoPoint": {"lat": 44.69825, "lon": 10.63125}}, {"facility": "Novartis Investigative Site", "city": "Verona", "state": "VR", "zip": "37126", "country": "Italy", "geoPoint": {"lat": 45.4299, "lon": 10.98444}}, {"facility": "Novartis Investigative Site", "city": "Cheongju-si", "state": "Chungcheongbuk-do", "zip": "28644", "country": "Korea, Republic of", "geoPoint": {"lat": 36.63722, "lon": 127.48972}}, {"facility": "Novartis Investigative Site", "city": "Bucheon-Si", "state": "Gyeonggi-Do", "zip": "14584", "country": "Korea, Republic of", "geoPoint": {"lat": 37.49889, "lon": 126.78306}}, {"facility": "Novartis Investigative Site", "city": "Suwon", "state": "Gyeonggi-do", "zip": "16499", "country": "Korea, Republic of", "geoPoint": {"lat": 37.29111, "lon": 127.00889}}, {"facility": "Novartis Investigative Site", "city": "Seoul", "state": "Korea", "zip": "08308", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Novartis Investigative Site", "city": "Gwangju", "zip": "501-757", "country": "Korea, Republic of", "geoPoint": {"lat": 35.15472, "lon": 126.91556}}, {"facility": "Novartis Investigative Site", "city": "Seoul", "zip": "120-752", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Novartis Investigative Site", "city": "Seoul", "zip": "156-755", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Novartis Investigative Site", "city": "M\u00e9xico, D.F.", "state": "Distrito Federal", "zip": "06700", "country": "Mexico"}, {"facility": "Novartis Investigative Site", "city": "Guadalajara", "state": "Jalisco", "zip": "44130", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Novartis Investigative Site", "city": "Panama City", "country": "Panama", "geoPoint": {"lat": 8.9936, "lon": -79.51973}}, {"facility": "Novartis Investigative Site", "city": "Bialystok", "zip": "15-276", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"facility": "Novartis Investigative Site", "city": "Lodz", "zip": "90-153", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"facility": "Novartis Investigative Site", "city": "Coimbra", "zip": "3041-853", "country": "Portugal", "geoPoint": {"lat": 40.20564, "lon": -8.41955}}, {"facility": "Novartis Investigative Site", "city": "Lisboa", "zip": "1169-024", "country": "Portugal", "geoPoint": {"lat": 38.71667, "lon": -9.13333}}, {"facility": "Novartis Investigative Site", "city": "Lisboa", "zip": "1749-035", "country": "Portugal", "geoPoint": {"lat": 38.71667, "lon": -9.13333}}, {"facility": "Novartis Investigative Site", "city": "Porto", "zip": "4100-180", "country": "Portugal", "geoPoint": {"lat": 41.14961, "lon": -8.61099}}, {"facility": "Novartis Investigative Site", "city": "Vila Nova de Gaia", "zip": "4434-502", "country": "Portugal", "geoPoint": {"lat": 41.13363, "lon": -8.61742}}, {"facility": "Novartis Investigative Site", "city": "Bucuresti", "state": "District 1", "zip": "10457", "country": "Romania", "geoPoint": {"lat": 44.42802, "lon": 26.09665}}, {"facility": "Novartis Investigative Site", "city": "Bucharest", "state": "District 3", "zip": "030303", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"facility": "Novartis Investigative Site", "city": "Bucharest", "state": "District 3", "zip": "030317", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"facility": "Novartis Investigative Site", "city": "Constanta", "state": "Jud. Constanta", "zip": "900002", "country": "Romania", "geoPoint": {"lat": 44.18073, "lon": 28.63432}}, {"facility": "Novartis Investigative Site", "city": "Bucharest", "state": "ROM", "zip": "12071", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"facility": "Novartis Investigative Site", "city": "Brasov", "zip": "500086", "country": "Romania", "geoPoint": {"lat": 45.64861, "lon": 25.60613}}, {"facility": "Novartis Investigative Site", "city": "Brasov", "zip": "500112", "country": "Romania", "geoPoint": {"lat": 45.64861, "lon": 25.60613}}, {"facility": "Novartis Investigative Site", "city": "Brasov", "zip": "500281", "country": "Romania", "geoPoint": {"lat": 45.64861, "lon": 25.60613}}, {"facility": "Novartis Investigative Site", "city": "Bucuresti", "zip": "011461", "country": "Romania", "geoPoint": {"lat": 44.42802, "lon": 26.09665}}, {"facility": "Novartis Investigative Site", "city": "Bucuresti", "zip": "050159", "country": "Romania", "geoPoint": {"lat": 44.42802, "lon": 26.09665}}, {"facility": "Novartis Investigative Site", "city": "Cluj Napoca", "zip": "400139", "country": "Romania", "geoPoint": {"lat": 46.76667, "lon": 23.6}}, {"facility": "Novartis Investigative Site", "city": "Cluj-Napoca", "zip": "400371", "country": "Romania", "geoPoint": {"lat": 46.76667, "lon": 23.6}}, {"facility": "Novartis Investigative Site", "city": "Pitesti", "zip": "110114", "country": "Romania", "geoPoint": {"lat": 44.85, "lon": 24.86667}}, {"facility": "Novartis Investigative Site", "city": "Barnaul", "zip": "656045", "country": "Russian Federation", "geoPoint": {"lat": 53.36056, "lon": 83.76361}}, {"facility": "Novartis Investigative Site", "city": "Chelyabinsk", "zip": "454000", "country": "Russian Federation", "geoPoint": {"lat": 55.15402, "lon": 61.42915}}, {"facility": "Novartis Investigative Site", "city": "Chelyabinsk", "zip": "454021", "country": "Russian Federation", "geoPoint": {"lat": 55.15402, "lon": 61.42915}}, {"facility": "Novartis Investigative Site", "city": "Moscow", "zip": "119992", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Novartis Investigative Site", "city": "Moscow", "zip": "125315", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Novartis Investigative Site", "city": "Moscow", "zip": "127018", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Novartis Investigative Site", "city": "N.Novgorod", "zip": "603126", "country": "Russian Federation"}, {"facility": "Novartis Investigative Site", "city": "Nizhny Novgorod", "zip": "603018", "country": "Russian Federation", "geoPoint": {"lat": 56.32867, "lon": 44.00205}}, {"facility": "Novartis Investigative Site", "city": "Penza", "zip": "440026", "country": "Russian Federation", "geoPoint": {"lat": 53.20066, "lon": 45.00464}}, {"facility": "Novartis Investigative Site", "city": "Ryazan", "zip": "390026", "country": "Russian Federation", "geoPoint": {"lat": 54.6269, "lon": 39.6916}}, {"facility": "Novartis Investigative Site", "city": "Saint Petersburg", "zip": "197022", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Novartis Investigative Site", "city": "Saratov", "zip": "410012", "country": "Russian Federation", "geoPoint": {"lat": 51.54056, "lon": 46.00861}}, {"facility": "Novartis Investigative Site", "city": "St-Petersburg", "zip": "193312", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Novartis Investigative Site", "city": "St. Petersburg", "zip": "194354", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Novartis Investigative Site", "city": "Yaroslavl", "zip": "150003", "country": "Russian Federation", "geoPoint": {"lat": 57.62987, "lon": 39.87368}}, {"facility": "Novartis Investigative Site", "city": "Singapore", "zip": "169608", "country": "Singapore", "geoPoint": {"lat": 1.28967, "lon": 103.85007}}, {"facility": "Novartis Investigative Site", "city": "Singapore", "zip": "308433", "country": "Singapore", "geoPoint": {"lat": 1.28967, "lon": 103.85007}}, {"facility": "Novartis Investigative Site", "city": "Bratislava", "state": "Slovak Republic", "zip": "831 03", "country": "Slovakia", "geoPoint": {"lat": 48.14816, "lon": 17.10674}}, {"facility": "Novartis Investigative Site", "city": "Nitra", "state": "Slovak Republic", "zip": "949 01", "country": "Slovakia", "geoPoint": {"lat": 48.30763, "lon": 18.08453}}, {"facility": "Novartis Investigative Site", "city": "Bardejov", "zip": "085 01", "country": "Slovakia", "geoPoint": {"lat": 49.29175, "lon": 21.27271}}, {"facility": "Novartis Investigative Site", "city": "Bratislava", "zip": "826 06", "country": "Slovakia", "geoPoint": {"lat": 48.14816, "lon": 17.10674}}, {"facility": "Novartis Investigative Site", "city": "Kosice", "zip": "04001", "country": "Slovakia", "geoPoint": {"lat": 48.71395, "lon": 21.25808}}, {"facility": "Novartis Investigative Site", "city": "Prievidza", "zip": "97101", "country": "Slovakia", "geoPoint": {"lat": 48.77446, "lon": 18.6275}}, {"facility": "Novartis Investigative Site", "city": "Ruzomberok", "zip": "034 26", "country": "Slovakia", "geoPoint": {"lat": 49.0748, "lon": 19.30751}}, {"facility": "Novartis Investigative Site", "city": "Trencin", "zip": "91101", "country": "Slovakia", "geoPoint": {"lat": 48.89452, "lon": 18.04436}}, {"facility": "Novartis Investigative Site", "city": "Cape Town", "zip": "7505", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Novartis Investigative Site", "city": "Cape Town", "zip": "7531", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Novartis Investigative Site", "city": "Durban", "zip": "4001", "country": "South Africa", "geoPoint": {"lat": -29.8579, "lon": 31.0292}}, {"facility": "Novartis Investigative Site", "city": "Aydin", "zip": "09100", "country": "Turkey", "geoPoint": {"lat": 37.84501, "lon": 27.83963}}, {"facility": "Novartis Investigative Site", "city": "Fatih / Istanbul", "zip": "34098", "country": "Turkey"}, {"facility": "Novartis Investigative Site", "city": "Istanbul", "zip": "34093", "country": "Turkey", "geoPoint": {"lat": 41.01384, "lon": 28.94966}}, {"facility": "Novartis Investigative Site", "city": "Istanbul", "zip": "34854", "country": "Turkey", "geoPoint": {"lat": 41.01384, "lon": 28.94966}}, {"facility": "Novartis Investigative Site", "city": "Izmir", "zip": "35040", "country": "Turkey", "geoPoint": {"lat": 38.41273, "lon": 27.13838}}, {"facility": "Novartis Investigative Site", "city": "Mersin", "zip": "33079", "country": "Turkey", "geoPoint": {"lat": 36.79526, "lon": 34.61792}}, {"facility": "Novartis Investigative Site", "city": "Bradford", "state": "West Yorkshire", "zip": "BD9 6RJ", "country": "United Kingdom", "geoPoint": {"lat": 53.79391, "lon": -1.75206}}, {"facility": "Novartis Investigative Site", "city": "Birmingham", "zip": "B9 5SS", "country": "United Kingdom", "geoPoint": {"lat": 52.48142, "lon": -1.89983}}, {"facility": "Novartis Investigative Site", "city": "East Yorkshire", "zip": "HU16 5JQ", "country": "United Kingdom"}, {"facility": "Novartis Investigative Site", "city": "Southampton", "zip": "SO16 6YD", "country": "United Kingdom", "geoPoint": {"lat": 50.90395, "lon": -1.40428}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "The treatment arms for QGE031 and placebo were pooled into high dose QGE031 (240 mg q2w, 240 mg q4w, 180 mg q2w and 120 q2w), low dose QGE031 (36 mg q2w and 18 mg 2qw) and Placebo Total (all QGE031 placebo and Omalizumab placebo arms).", "recruitmentDetails": "A total of 471 participants were randomized to one of the 14 treatment groups. Of these, 5 participants did not receive study treatment. Therefore, the full analysis set (FAS) and safety set included 466 participants.", "groups": [{"id": "FG000", "title": "QGE031 High Dose", "description": "Participants received QGE031 240 mg q2w, 240 mg q4w, 180 mg q2w or 120 mg q2w."}, {"id": "FG001", "title": "QGE031 Low Dose", "description": "Participants received QGE031 36 mg q2w or 18 mg q2w."}, {"id": "FG002", "title": "Omalizumab", "description": "Participants received omalizumab as per locally approved dosing table q2w or q4w."}, {"id": "FG003", "title": "Placebo Total", "description": "Participants received matching placebo to QGE031 or Omalizumab."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "199"}, {"groupId": "FG001", "numSubjects": "40"}, {"groupId": "FG002", "numSubjects": "135"}, {"groupId": "FG003", "numSubjects": "97"}]}, {"type": "FAS", "achievements": [{"groupId": "FG000", "numSubjects": "199"}, {"groupId": "FG001", "numSubjects": "40"}, {"groupId": "FG002", "numSubjects": "131"}, {"groupId": "FG003", "numSubjects": "96"}]}, {"type": "Safety Set", "achievements": [{"groupId": "FG000", "numSubjects": "199"}, {"groupId": "FG001", "numSubjects": "40"}, {"groupId": "FG002", "numSubjects": "131"}, {"groupId": "FG003", "numSubjects": "96"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "188"}, {"groupId": "FG001", "numSubjects": "36"}, {"groupId": "FG002", "numSubjects": "121"}, {"groupId": "FG003", "numSubjects": "89"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "14"}, {"groupId": "FG003", "numSubjects": "8"}]}], "dropWithdraws": [{"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Protocol deviation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "7"}, {"groupId": "FG003", "numSubjects": "2"}]}, {"type": "Non-compliance with study treatment", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "3"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Baseline characteristics were based on the FAS.", "groups": [{"id": "BG000", "title": "QGE031 High Dose", "description": "Participants received QGE031 240 mg q2w, 240 mg q4w, 180 mg q2w or 120 mg q2w."}, {"id": "BG001", "title": "QGE031 Low Dose", "description": "Participants received QGE031 36 mg q2w or 18 mg q2w."}, {"id": "BG002", "title": "Omalizumab", "description": "Participants received omalizumab as per locally approved dosing table q2w or q4w."}, {"id": "BG003", "title": "Placebo Total", "description": "Participants received matching placebo to QGE031 or Omalizumab."}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "199"}, {"groupId": "BG001", "value": "40"}, {"groupId": "BG002", "value": "135"}, {"groupId": "BG003", "value": "97"}, {"groupId": "BG004", "value": "471"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "47.6", "spread": "13.86"}, {"groupId": "BG001", "value": "46.0", "spread": "12.38"}, {"groupId": "BG002", "value": "46.8", "spread": "13.35"}, {"groupId": "BG003", "value": "48.6", "spread": "12.80"}, {"groupId": "BG004", "value": "47.4", "spread": "13.36"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "113"}, {"groupId": "BG001", "value": "20"}, {"groupId": "BG002", "value": "92"}, {"groupId": "BG003", "value": "63"}, {"groupId": "BG004", "value": "288"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "86"}, {"groupId": "BG001", "value": "20"}, {"groupId": "BG002", "value": "43"}, {"groupId": "BG003", "value": "34"}, {"groupId": "BG004", "value": "183"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Percentage of QGE031 Participants With Clinically Important Improvement of <= -0.5 in the Asthma Control Questionnaire 7 (ACQ-7) Score Compared to Placebo", "description": "The ACQ-7 measures asthma symptom control and consisted of 7 items: 5 on symptom assessment, 1 on rescue bronchodilator use and 1 on airway caliber (FEV1 % predicted). All 7 questions of the ACQ were equally weighted. Items 1-6 scored along a 7-point response scale, where 0 = good controlled and 6 = poor controlled. The 7th item on % predicted FEV1 (pre-bronchodilator) was scored by clinic staff on a 7-point scale (0 - \\> 95%; 1 - 90-95%; 2 - 80-89%; 3 - 70-79%; 4 - 60-69%; 5 - 50-59%; 6 - \\< 50%). The average score of the 7 questions was calculated as the sum of scores divided by the number of questions that were answered by the participants, as long as there were at least 6 questions answered and the missing items were neither question 1 nor question 7.", "populationDescription": "The full analysis set (FAS) for the QGE031 240 mg q2w, placebo to QGE031 240 mg q2w and Omalizumab groups (n=120,49,131) was considered for the analysis. Only participants who had week 16 values were analyzed. The FAS included randomized participants who received at least one dose of study drug.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Week 16", "groups": [{"id": "OG000", "title": "QGE031 240 mg q2w", "description": "Participants received QGE031 240 mg q2w."}, {"id": "OG001", "title": "Placebo to QGE031 240 mg q2w", "description": "Participants received placebo to QGE031 240 mg q2w"}, {"id": "OG002", "title": "Omalizumab", "description": "Participants received omalizumab as per locally approved dosing table q2w or q4w."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "114"}, {"groupId": "OG001", "value": "49"}, {"groupId": "OG002", "value": "131"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "63.16"}, {"groupId": "OG001", "value": "70.21"}, {"groupId": "OG002", "value": "69.17"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.576", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "0.79", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.35", "ciUpperLimit": "1.78"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.556", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "0.84", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.46", "ciUpperLimit": "1.52"}]}, {"type": "SECONDARY", "title": "Change From Baseline in ACQ-7 Score", "description": "The ACQ-7 measures asthma symptom control and consisted of 7 items: 5 on symptom assessment, 1 on rescue bronchodilator use and 1 on airway caliber (FEV1 % predicted). All 7 questions of the ACQ were equally weighted. Items 1-6 scored along a 7-point response scale, where 0 = good controlled and 6 = poor controlled. The 7th item on % predicted FEV1 (pre-bronchodilator) was scored by clinic staff on a 7-point scale (0 - \\> 95%; 1 - 90-95%; 2 - 80-89%; 3 - 70-79%; 4 - 60-69%; 5 - 50-59%; 6 - \\< 50%). The average score of the 7 questions was calculated as the sum of scores divided by the number of questions that were answered by the participants, as long as there were at least 6 questions answered and the missing items were neither question 1 nor question 7. A negative change from baseline indicates improvement.", "populationDescription": "The FAS for the QGE031 240 mg q2w, placebo to QGE031 240 mg q2w and Omalizumab groups (n=120,49,131) was considered for the analysis. Participants who had values at both baseline and the post baseline time point were analyzed for that post baseline time point. The FAS included randomized participants who received at least one dose of study drug.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Score on a scale", "timeFrame": "Baseline, Weeks 4, 8, 12, 16 and 28", "groups": [{"id": "OG000", "title": "QGE031 240 mg q2w", "description": "Participants received QGE031 240 mg q2w."}, {"id": "OG001", "title": "Placebo to QGE031 240 mg q2w", "description": "Participants received placebo to QGE031 240 mg q2w"}, {"id": "OG002", "title": "Omalizumab", "description": "Participants received omalizumab as per locally approved dosing table q2w or q4w."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "120"}, {"groupId": "OG001", "value": "49"}, {"groupId": "OG002", "value": "131"}]}], "classes": [{"title": "Week 4 (n=115,46,122)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.51", "spread": "0.709"}, {"groupId": "OG001", "value": "-0.48", "spread": "0.834"}, {"groupId": "OG002", "value": "-0.60", "spread": "0.705"}]}]}, {"title": "Week 8 (n=110,46,122)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.68", "spread": "0.678"}, {"groupId": "OG001", "value": "-0.62", "spread": "0.735"}, {"groupId": "OG002", "value": "-0.78", "spread": "0.687"}]}]}, {"title": "Week 12 (n=110,46,118)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.78", "spread": "0.738"}, {"groupId": "OG001", "value": "-0.71", "spread": "0.724"}, {"groupId": "OG002", "value": "-0.83", "spread": "0.737"}]}]}, {"title": "Week 16 (n=114,48,120)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.75", "spread": "0.817"}, {"groupId": "OG001", "value": "-0.79", "spread": "0.733"}, {"groupId": "OG002", "value": "-0.89", "spread": "0.734"}]}]}, {"title": "Week 28 (n112,47,115)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.62", "spread": "0.810"}, {"groupId": "OG001", "value": "-0.63", "spread": "0.744"}, {"groupId": "OG002", "value": "-0.59", "spread": "0.842"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With a Change From Baseline in ACQ-7 Score Less Than -1.1", "description": "The ACQ-7 measures asthma symptom control and consisted of 7 items: 5 on symptom assessment, 1 on rescue bronchodilator use and 1 on airway caliber (FEV1 % predicted). All 7 questions of the ACQ were equally weighted. Items 1-6 scored along a 7-point response scale, where 0 = good controlled and 6 = poor controlled. The 7th item on % predicted FEV1 (pre-bronchodilator) was scored by clinic staff on a 7-point scale (0 - \\> 95%; 1 - 90-95%; 2 - 80-89%; 3 - 70-79%; 4 - 60-69%; 5 - 50-59%; 6 - \\< 50%). The average score of the 7 questions was calculated as the sum of scores divided by the number of questions that were answered by the participants, as long as there were at least 6 questions answered and the missing items were neither question 1 nor question 7.", "populationDescription": "The full analysis set (FAS) for the QGE031 240 mg q2w, placebo to QGE031 240 mg q2w and Omalizumab groups (n=120,49,131) was considered for the analysis. Only participants who had week 16 values were analyzed. The FAS included randomized participants who received at least one dose of study drug.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Week 16", "groups": [{"id": "OG000", "title": "QGE031 240 mg q2w", "description": "Participants received QGE031 240 mg q2w."}, {"id": "OG001", "title": "Placebo to QGE031 240 mg q2w", "description": "Participants received placebo to QGE031 240 mg q2w"}, {"id": "OG002", "title": "Omalizumab", "description": "Participants received omalizumab as per locally approved dosing table q2w or q4w."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "114"}, {"groupId": "OG001", "value": "47"}, {"groupId": "OG002", "value": "120"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "40.35"}, {"groupId": "OG001", "value": "34.04"}, {"groupId": "OG002", "value": "36.67"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.483", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "1.32", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.61", "ciUpperLimit": "2.86"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.261", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "1.39", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.79", "ciUpperLimit": "2.44"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Score", "description": "The AQLQ is a 32-item disease specific questionnaire designed to measure functional impairments that are most important to participants with asthma. The 32 items in the AQLQ were divided into four domain-specific scores and a total score as follows: Activity limitations = Mean of Items 1, 2, 3, 4, 5, 11, 19, 25, 28, 31, 32 (11 items); Symptoms = Mean of Items 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 29, 30 (12 items); Emotional function = Mean of Items 7, 13, 15, 21, 27 (5 items); Environmental stimuli = Mean of Items 9, 17, 23, 26 (4 items); and Overall Score = Mean of Items 1 to 32 (32 items). Each item of the AQLQ was equally weighted and scored along a 7-point scale, where 1 indicates maximal impairment and 7 indicates no impairment. Thus, higher scores indicate better asthma-related quality of life. The mean overall score ranged from 1 to 7. A positive change from baseline indicates improvement.", "populationDescription": "The FAS for the QGE031 240 mg q2w, placebo to QGE031 240 mg q2w and Omalizumab groups (n=120,49,131) was considered for the analysis. Participants who had values at both baseline and the post baseline time point were analyzed for that post baseline time point. The FAS included randomized participants who received at least one dose of study drug.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Score on a scale", "timeFrame": "Baseline, Week 16, Week 28", "groups": [{"id": "OG000", "title": "QGE031 240 mg q2w", "description": "Participants received QGE031 240 mg q2w."}, {"id": "OG001", "title": "Placebo to QGE031 240 mg q2w", "description": "Participants received placebo to QGE031 240 mg q2w"}, {"id": "OG002", "title": "Omalizumab", "description": "Participants received omalizumab as per locally approved dosing table q2w or q4w."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "114"}, {"groupId": "OG001", "value": "48"}, {"groupId": "OG002", "value": "122"}]}], "classes": [{"title": "Week 16 (n=114,48,122)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.53", "spread": "0.878"}, {"groupId": "OG001", "value": "0.66", "spread": "0.624"}, {"groupId": "OG002", "value": "0.79", "spread": "0.853"}]}]}, {"title": "Week 28 (n=114,47,121)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.44", "spread": "0.899"}, {"groupId": "OG001", "value": "0.63", "spread": "0.826"}, {"groupId": "OG002", "value": "0.48", "spread": "0.871"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean Number of Puffs of Morning, Evening and Total Daily Asthma Rescue Medication", "description": "Participants recorded their use of rescue medication into an electronic diary (eDiary). A negative change from baseline indicates improvement.", "populationDescription": "The full analysis set (FAS) for the QGE031 240 mg q2w, placebo to QGE031 240 mg q2w and Omalizumab groups (n=120,49,131) was considered for the analysis. Only participants who had both baseline and week 16 values were analyzed. The FAS included randomized participants who received at least one dose of study drug.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Number of puffs", "timeFrame": "Baseline, Week 16", "groups": [{"id": "OG000", "title": "QGE031 240 mg q2w", "description": "Participants received QGE031 240 mg q2w."}, {"id": "OG001", "title": "Placebo to QGE031 240 mg q2w", "description": "Participants received placebo to QGE031 240 mg q2w"}, {"id": "OG002", "title": "Omalizumab", "description": "Participants received omalizumab as per locally approved dosing table q2w or q4w."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "117"}, {"groupId": "OG001", "value": "48"}, {"groupId": "OG002", "value": "122"}]}], "classes": [{"title": "Morning", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.28", "spread": "0.072"}, {"groupId": "OG001", "value": "-0.34", "spread": "0.113"}, {"groupId": "OG002", "value": "-0.39", "spread": "0.073"}]}]}, {"title": "Evening", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.31", "spread": "0.082"}, {"groupId": "OG001", "value": "-0.33", "spread": "0.126"}, {"groupId": "OG002", "value": "-0.33", "spread": "0.084"}]}]}, {"title": "Overall", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.56", "spread": "0.145"}, {"groupId": "OG001", "value": "-0.64", "spread": "0.226"}, {"groupId": "OG002", "value": "-0.73", "spread": "0.148"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Morning", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.604", "statisticalMethod": "Repeated measures mixed model"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Morning", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.260", "statisticalMethod": "Repeated measures mixed model"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Evening", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.937", "statisticalMethod": "Repeated measures mixed model"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Evening", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.880", "statisticalMethod": "Repeated measures mixed model"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Overall daily", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.762", "statisticalMethod": "Repeated measures mixed model"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Overall daily", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.408", "statisticalMethod": "Repeated measures mixed model"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "QGE031 High Dose", "description": "Participants received QGE031 240 mg q2w, 240 mg q4w, 180 mg q2w or 120 mg q2w.", "seriousNumAffected": 9, "seriousNumAtRisk": 199, "otherNumAffected": 91, "otherNumAtRisk": 199}, {"id": "EG001", "title": "QGE031 Low Dose", "description": "Participants received QGE031 36 mg q2w or 18 mg q2w.", "seriousNumAffected": 3, "seriousNumAtRisk": 40, "otherNumAffected": 17, "otherNumAtRisk": 40}, {"id": "EG002", "title": "Omalizumab", "description": "Participants received omalizumab as per locally approved dosing table q2w or q4w.", "seriousNumAffected": 1, "seriousNumAtRisk": 131, "otherNumAffected": 43, "otherNumAtRisk": 131}, {"id": "EG003", "title": "Placebo Total", "description": "Participants received matching placebo to QGE031 or Omalizumab", "seriousNumAffected": 5, "seriousNumAtRisk": 96, "otherNumAffected": 35, "otherNumAtRisk": 96}], "seriousEvents": [{"term": "Haemorrhagic anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA (18.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 199}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 131}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 96}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (18.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 199}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 131}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 96}]}, {"term": "Ventricular arrhythmia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (18.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 199}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 131}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 96}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (18.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 199}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 40}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 131}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 96}]}, {"term": "Drug hypersensitivity", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA (18.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 199}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 131}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 96}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (18.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 199}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 131}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 96}]}, {"term": "Impetigo", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (18.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 199}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 131}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 96}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (18.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 199}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 131}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 96}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (18.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 199}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 131}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 96}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (18.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 199}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 131}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 96}]}, {"term": "Viral upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (18.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 199}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 131}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 96}]}, {"term": "Femur fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (18.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 199}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 131}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 96}]}, {"term": "Vaginal laceration", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (18.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 199}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 131}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 96}]}, {"term": "Alanine aminotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (18.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 199}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 131}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 96}]}, {"term": "Aspartate aminotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (18.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 199}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 131}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 96}]}, {"term": "Blood lactate dehydrogenase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (18.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 199}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 131}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 96}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (18.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 199}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 131}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 96}]}, {"term": "Bursitis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (18.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 199}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 131}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 96}]}, {"term": "Intervertebral disc protrusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (18.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 199}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 131}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 96}]}, {"term": "Haematuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (18.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 199}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 131}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 96}]}, {"term": "Renal colic", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (18.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 199}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 40}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 131}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 96}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (18.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 199}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 40}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 131}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 96}]}, {"term": "Laryngeal dysplasia", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (18.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 199}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 131}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 96}]}, {"term": "Pulmonary oedema", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (18.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 199}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 131}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 96}]}, {"term": "Urticaria", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (18.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 199}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 131}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 96}]}], "otherEvents": [{"term": "Injection site reaction", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (18.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 57, "numAtRisk": 199}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 40}, {"groupId": "EG002", "numAffected": 19, "numAtRisk": 131}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 96}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (18.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 16, "numAtRisk": 199}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 40}, {"groupId": "EG002", "numAffected": 9, "numAtRisk": 131}, {"groupId": "EG003", "numAffected": 9, "numAtRisk": 96}]}, {"term": "Viral upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (18.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 199}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 40}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 131}, {"groupId": "EG003", "numAffected": 6, "numAtRisk": 96}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (18.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 44, "numAtRisk": 199}, {"groupId": "EG001", "numAffected": 13, "numAtRisk": 40}, {"groupId": "EG002", "numAffected": 19, "numAtRisk": 131}, {"groupId": "EG003", "numAffected": 27, "numAtRisk": 96}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Czech Republic", "Denmark", "Spain"]}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000069444", "term": "Omalizumab"}], "ancestors": [{"id": "D000018926", "term": "Anti-Allergic Agents"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}], "browseLeaves": [{"id": "M413", "name": "Omalizumab", "asFound": "Enriched", "relevance": "HIGH"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}